Equitable Trust Co. Invests $252,000 in Hologic, Inc. (NASDAQ:HOLX)

Equitable Trust Co. acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to its most recent filing with the SEC. The firm acquired 3,099 shares of the medical equipment provider’s stock, valued at approximately $252,000.

Several other institutional investors also recently bought and sold shares of HOLX. Innealta Capital LLC purchased a new stake in shares of Hologic in the second quarter valued at about $25,000. Wolff Wiese Magana LLC acquired a new position in Hologic during the 3rd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new position in Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the 2nd quarter worth approximately $37,000. Finally, Cromwell Holdings LLC lifted its holdings in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $78.76 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.32 and a current ratio of 3.69. The business’s fifty day moving average price is $80.97 and its two-hundred day moving average price is $78.16. The stock has a market cap of $18.29 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a one year low of $66.93 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the company earned $0.89 earnings per share. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of several research analyst reports. Leerink Partners cut their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Finally, Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.